Summarized by Masters of Longevity from Startupticker.ch.
Roundup of recent biotech regulatory wins, positive mid/late-stage trial results, and a partnership advancing new anti-infective and respiratory medicines.
Key Takeaways
- BioVersys received FDA Fast Track designation for BV100 targeting carbapenem-resistant Acinetobacter pneumonia.
- Windward Bio reported positive Phase 2 interim results for twice-yearly WIN378 showing favorable safety and lung function effects.
- Torqur AG secured EU orphan drug designation for bimiralisib for thymic epithelial tumours, granting regulatory incentives and market exclusivity.
